Business Wire

1. Sucampo Presents Data For AMITIZA In The Treatment Of Moderate To Very Severe Irritable Bowel Syndrome With Constipation (IBS-C)
   5/20/2012

   Sucampo Pharmaceuticals, Inc. recently announced the presentation of pooled data from post-hoc analyses of the two pivotal Phase 3 studies of AMITIZA (lubiprostone) for the treatment of irritable bowel syndrome with constipation (IBS-C) at Digestive Disease Week 2012 in San Diego.

2. ACRO Takes To Video To Advise FDA On Innovation
   5/18/2012

   Building on its recent testimony to the FDA on modernizing clinical trials, the Association of Clinical Research Organizations (ACRO) has released a new video exhorting the FDA to demonstrate “bold leadership” to help make the drug development process less expensive, faster and more productive.

3. Pfizer Provides Topline Results From Phase 3 Study Of Torisel As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC)
   5/15/2012

   Pfizer Inc announced recently that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib. 

4. Maxygen To Receive $30M Payment From Bayer
   5/14/2012

   Maxygen, Inc., a biopharmaceutical company, recently announced that it will receive a $30.0M payment from Bayer HealthCare LLC in connection with Bayer’s continued clinical development of a recombinant factor VIIa product candidate for the treatment of hemophilia.

5. GE Healthcare Life Sciences Completes Acquisition Of Xcellerex, Inc.
   5/10/2012

   GE Healthcare, the healthcare business of GE (NYSE: GE) announced today that it has completed the acquisition of Xcellerex, Inc., a supplier of innovative manufacturing technologies for the fast-growing biopharmaceutical industry.

6. FDA Arthritis Advisory Committee Recommends Approval Of Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
   5/9/2012

   Pfizer Inc. (NYSE:PFE) announced today that the Arthritis Advisory Committee to the U.S. Food and Drug Administration (FDA) voted 8-2 to recommend approval of the investigational agent tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

7. Liquidity Services, Inc. To Acquire GoIndustry DoveBid
   5/9/2012

   GoIndustry DoveBid shareholders to receive 73 pence per share in cash Liquidity Services, Inc. /quotes/zigman/99863/quotes/nls/lqdt LQDT -0.09% which provides leading corporations, public sector agencies and buying customers the world's most transparent, innovative and effective online marketplaces and integrated services for surplus assets, today announced it has agreed to acquire GoIndustry DoveBid, plc (GoIndustry), a global provider of surplus asset management, auction and valuation services, for 73 pence per share and assumed indebtedness, or total consideration of approximately $31 million USD. 

8. Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ (desvenlafaxine) 50 mg/day For The Treatment Of Major Depressive Disorder In Adults
   5/7/2012

   Pfizer Inc. announced new data presented at the 165th Annual Meeting of the American Psychiatric Association (APA) in Philadelphia on PRISTIQ (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder (MDD) in adults,1 including a long-term relapse prevention study. 

9. GE Capital Closes $7.5M In Senior Secured Facilities For PharmAthene
   4/30/2012

   GE Capital, Healthcare Financial Services announced recently that it was sole lender and administrative agent on $7.5M in senior secured credit facilities for PharmAthene, consisting of a $2.5M term loan and a $5M revolving line of credit.

10. Merck Wins U.S. ZETIA (ezetimibe)/ VYTORIN (ezetimibe/simvastatin) Patent Infringement Lawsuit
    4/27/2012

    Merck, known as MSD outside the United States and Canada, announced today that the U.S. District Court for the District of New Jersey has ruled in Merck's favor in two jointly related patent infringement suits against Mylan Pharmaceuticals Inc. "The court appropriately ruled that the patent for ZETIA and VYTORIN in the U.S. is valid and enforceable," said Bruce N. Kuhlik, executive vice president and general counsel of Merck.